Skip to main
ABEO

Abeona Therapeutics (ABEO) Stock Forecast & Price Target

Abeona Therapeutics (ABEO) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Abeona Therapeutics is expected to see significant growth in the coming years, with their ZEVASKYN gene therapy for RDEB projected to generate over $97M in revenue by 2027. Despite concerns about manufacturing bottlenecks and engraftment failures, the company is expanding their QTC network and showing steady adoption of ZEVASKYN. With a risk-adjusted net present value of $1B and a total firm value of $1.15B, the stock has potential for strong long-term growth, although there are risks such as slower uptake and potential dilution.

Bears say

Abeona Therapeutics is facing logistical hurdles with its limited experience in the process and product of gene and cell therapy, leading to production and scheduling delays and variability. Despite patient and clinician enthusiasm for pz-cel's potential, the company's limited commercial success with its approved product ZEVASKYN and potential competition from Vyjuvek position it as a complementary therapy option. While its AAV-based gene therapy programs provide further upside potential, current challenges and limited commercial success suggest a negative outlook for Abeona Therapeutics.

Abeona Therapeutics (ABEO) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abeona Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abeona Therapeutics (ABEO) Forecast

Analysts have given Abeona Therapeutics (ABEO) a Buy based on their latest research and market trends.

According to 2 analysts, Abeona Therapeutics (ABEO) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abeona Therapeutics (ABEO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.